Possibility to comment on information content of national risk medicines classification
The national risk medicines classification lists high-risk medicines whose use requires special attention. Information content for the classification was compiled in 2022 in a project coordinated by Fimea and implemented with stakeholders utilising the Delphi research method.
The national risk medicines classification is intended for use by health care professionals and helps to identify key high-risk medicines in different operational environments of social welfare and health care. The classification supports clinical decision-making and the planning and implementation of pharmacotherapies at different stages of the pharmacotherapy process
Before the publication of the classification, we offer its future users the possibility to comment on the information content that has been formed. Public commentary will be accepted in January-February 2023. At that time, we will approach key stakeholders with targeted messages, and we will provide more detailed information on the matter on the Fimea website.
The national risk medicines classification, high-risk medicines, and the composition of the project's working group.
- Elsi Similä, Project Manager, tel. +358 29 522 3607
- E-mails take the form email@example.com